Risk factor
Very high price volatility
Profitability factor
Very strong margins and returns
About
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBIT
Target Price
The average target price of 2268.HK is 79 and suggests 37% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre